Thursday Sep 11
Quest Diagnostics Offers A Good Long-Term Opportunity
Quest Diagnostics Q2 FY2014 revenue from continuing operations grew 4.8% to $1.9 billion, while EPS grew 1.9% to $1.08. Quest Diagnostics and Lab Corps have perfected the game of consolidating and standardizing lab tests, and eliminate smaller competitors through acquisitions.
Tue Sep 09, 2014
Australia court upholds patent on human genetic material
Patient advocacy group Cancer Voices Australia [advocacy website] appealed a February 2013 court ruling that approved the patentability of nucleic acids that the company has been able to extract from mutated versions of the BRCA1 gene, a gene that has been linked with certain cancers, including ovarian and breast cancer. By studying the naturally occurring mutations within the BRCA1 gene, scientists can better predict [ The Scientist report] whether a woman is at risk for certain breast and ovarian cancers.
Federal Circuit Frames Test for Patent-Eligibility
Personalized medicine relies on diagnostics to analyze a patient for individualized therapy and for monitoring a patient's health status. Some diagnostic tests use natural products, for example gene sequences, either as the target of the diagnostic test or as a tool to identify a genetic trait or anomaly.
Myriad myPath(TM) Melanoma Test Reduced Indeterminate Cases by 76...
Myriad Genetics, Inc. today presented results from a pivotal clinical utility study of the Myriad myPath Melanoma test at the 2014 College of American Pathologists annual meeting in Chicago, Ill. Myriad myPath Melanoma is a novel diagnostic test that differentiates malignant melanoma from benign skin lesions with greater than 90 percent accuracy and helps physicians deliver a more objective and confident diagnosis for patients.
Mon Sep 08, 2014
Myriad Genetics Receives Average Rating of "Hold" from Brokerages
Myriad Genetics has been given a consensus rating of "Hold" by the seventeen ratings firms that are currently covering the company, American Banking News.com reports . One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company.
Medical News Today
Study: Myriad myRisk Hereditary Cancer test identifies 43 percent...
Myriad Genetics, Inc. has announced that the Myriad myRisk Hereditary Cancer test significantly improved the detection of cancer-causing mutations by 46 percent in patients with breast cancer in a new study published in the journal Cancer . In this study, researchers at Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center used the myRisk test to determine the frequency of hereditary cancer mutations in 2,158 individuals with a history of breast cancer, including 1,781 referred for commercial BRCA1/2 testing, and 377 patients with a personal and family history who previously tested negative for BRCA mutations.
Sun Sep 07, 2014
Australia: Myriad Gene Patents Look Good
Guest post by Ben McEniery. McEniery is a Senior Lecturer in Law at the Queensland University of Technology and a Barrister who specialises in Intellectual Property Law matters.
Fri Sep 05, 2014
- Full Federal Court Confirms Patentability of Isolated Genes
A five-judge bench of the Full Court of the Federal Court of Australia has today unanimously decided that Myriad Genetics Inc's patent covering the isolated BRCA1 gene is patentable subject matter in Australia. The Full Court elected not to follow the reasoning of the U.S. Supreme Court, when it found in 2013 that certain claims of a closely related U.S. Patent of Myriad were invalid, as the claim to isolated nucleic acid was a claim to a "product of nature" and not patentable subject matter.
Australian Broadcasting Corporation
Federal Court says US company can patent breast cancer gene
Cancer survivors and their advocates have been left devastated by a Federal Court ruling which gives private companies the right to control human genes. EMMA ALBERICI, PRESENTER: Critics have slammed a Federal Court decision that allows a US biotechnology company to maintain a commercial monopoly over a key breast cancer gene.
Sydney Morning Herald
Gene decision fuels calls for legal change
Corporations can continue owning the rights to human genes thanks to a federal court ruling but patients at the heart of the legal battle say the practice is immoral. Central to the test case, between support group Cancer Voices Australia and US biotech company Myriad Genetics, is the susceptibility gene known as BRCA1.
Thu Sep 04, 2014
Mutation of breast cancer gene can be patented, says Federal Court
Cancer patients and doctors are devastated at a decision by the full bench of the Federal Court this morning that private companies have the right to control human genes. They fear the decision in the so-called "breast cancer gene" case, which found a company could patent a mutation in the gene BRCA1, will stifle research and lead to far higher costs for patients in need of potentially life-saving tests.
Wed Sep 03, 2014
Myriad Publishes myRisk Hereditary Cancer Study In Cancer
Myriad Genetics, Inc. , today announced that the Myriad myRiska Hereditary Cancer test significantly improved the detection of cancer-causing mutations by 46 percent in patients with breast cancer in a new study published in the journal Cancer .
Short Interest in Myriad Genetics Drops By 4.2%
Myriad Genetics was the target of a significant drop in short interest during the month of August.
Tue Sep 02, 2014
The USPTO Issues Guidelines for Subject Matter Eligibility in view of ...
The U.S. Supreme Court's decisions in Molecular Pathology v. Myriad Genetics, Inc. and Mayo Collaborative Services v.
Thu Aug 28, 2014
What to do About All These Invalid Patents?
The recorder-of-deeds here in Boone County Missouri is pretty good at her job. Although there is an occasional error in the records, those errors are quickly remedied once found.
Myriad Genetics to Present at the Morgan Stanley Healthcare Conference
Myriad Genetics, Inc. announced today that Mark Capone, president of Myriad Genetics Laboratories, is scheduled to present at the Morgan Stanley Healthcare Conference at 9:45 a.m. Eastern time on September 10, 2014, at the Grand Hyatt in New York City.
Wed Aug 27, 2014
Guest Post: Myriad-Mayo Guidance -- Consistency With International Harmonization and TRIPS
It is strongly arguable that insofar as the USPTO's Myriad-Mayo Guidance  dismisses as non-eligible newly isolated substances , nucleotide sequences and microorganisms having new utility or producing new technical effects it is in conflict with the Agreement on Trade-Related Aspects of Intellectual Property Rights  .
Critical Alerts For Vodafone Group, Tim Hortons, Transocean, Myriad...
To see what our analysts have discovered about a particular stock, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
Mon Aug 25, 2014
Myriad Genetics' Patents Are Facing Trouble Again
As I noted earlier, the 2013 Supreme Court ruling declared that isolated human genes are not patentable, which significantly challenged Myriad's patent landscape.
Fri Aug 22, 2014
Examination of Myriad-Mayo Guidance Comments -- AUTM, COGR, AAU, and APLU
On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural Products" , to implement a new procedure for determining the subject matter eligibility of claims under 35 U.S.C. 101 in view of the ... (more)